L7 Informatics provides a unified platform, L7|ESP®, that contextualizes data and eliminates business silos via process orchestration.

Austin, TX
Joined October 2012
What if a #manufacturing recipe behaved like source code? Structured, versioned, and able to move from lab to plant without a single value being retyped. L7's Marcia Blackmoore makes the case for it in her latest article: bit.ly/4z15MFK #CMC #TechTransfer #AI
15
When a CRDMO misses a stability pull, how long until your portfolio team knows? L7 PLM gives sponsors and CRDMOs one governed, bi-directional CMC record. At PPM Summit Boston? Meet our Founder & CEO @vrangadass and CCO Marcia Blackmoore. ▶ Datasheet: bit.ly/4yfmGiR
21
Legacy architectures trap critical scientific data in brittle, disconnected silos. #L7ESP unifies the entire #CMC lifecycle, from scale-up to manufacturing, on a single, AI-actionable substrate. ▶ Full video: bit.ly/474o5xI #Pharma #Biomanufacturing #GxP #AgenticAI
37
AI is accelerating drug discovery, but it is also tightening the choke point at CMC. @vrangadass, Ph.D., makes the case for CMC-in-the-Loop: bit.ly/3TNjVHj The bottom line is you cannot solve an enterprise orchestration problem with localized lab tools. #CMC #Pharma
20
This Thursday at #CellAndGeneTherapy International, L7's Marcia Blackmoore joins Arvind Natarajan (Iovance Biotherapeutics), Mayo Pujols (Kyverna Therapeutics), and Pooja Sabhachandani (Novartis) for a candid panel discussion. Join us for the session or stop by Booth #1508!
35
AI won't transform CMC until we transform the underlying data. Tomorrow at #LotFEurope, @vrangadass will share the stage with leaders from J&J, Sanofi, Bayer, and QbDVision to outline the exact data foundations needed for true agentic process development. Catch us there!
20
AI models are only 1.6–2% of the software footprint. The other 98% is orchestration, context, and governance. The pragmatic middle path exists: keep the point-solution capabilities you need, but overlay them with one data model and execution layer. Read: bit.ly/4zWzVao
1
37
Scaling precision science is a journey. L7|ESP® was built from day one to give you a single, unified foundation. With 2026.1, we're giving your teams the speed and intelligence to execute faster, safer, and at scale. See L7|ESP 2026.1 in action: bit.ly/4zowDwf
1
22
Agentic AI needs an operating system. L7|ESP® has been that foundation from day 1. Structured data, connected systems, governed workflows, giving agents somewhere to work. @vrangadass at @LabOfTheFuture Europe Day 1 | 16:20 | Digital CMC Track Booth #14 | Sept. 22-23 #LotFEurope
21
"How do we govern AI?" is one of the most common questions in pharma right now, and one of the hardest to answer well. Our CEO, @vrangadass, on why governance has to exist in the operational fabric before an agent acts: bit.ly/3TlxLQN #AI #Pharma #Governance
10
Your #AI can probably summarize every paper ever published on your #molecule, yet it has no idea what happened on your floor last night. That gap is architectural, and our new #whitepaper lays it all out, incl. AI compliance under 21 CFR Part 11 and GAMP 5. Link in comment ▼
1
12
We are delighted to welcome Ray Veeraraghavan, Ph.D., to L7 as VP of Science & AI. Best part: Ray first knew L7|ESP as the customer who evaluated and selected it. Now he joins to lead scientific content strategy & drive adoption of L7|SYNAPSE Agentic AI. Link to release below.
1
1
11
Another Gartner® Hype Cycle™ mention for @L7informatics! Proud to be named in the latest Gartner® Hype Cycle™ for Process Manufacturing Technologies as a Sample Vendor for Laboratory Informatics Suites. Learn more about L7|ESP®: bit.ly/4vw684K
11
250 years of big ideas, and the best ones are still ahead. Today we're grateful for the people who make the work meaningful: our customers, our partners, our team members, and the broader life sciences community pushing every day to move science forward. #FourthOfJuly
1
1
9
Happy 4th of July from all of us at L7!
7
Researchers examined Anthropic's Claude Code and found that only ~1.6% of it was attributable to the AI making decisions. The other 98% was the architecture around it. In regulated pharma, that 98% is where trust, compliance, and real advantage get built. @vrangadass on why ⬇
1
1
27